{"classes":[{"categories":[{"measurements":[{"comment":"Below the lower limit of quantification","groupId":"OG000","spread":"NA","value":"NA"}]}],"title":"Day 1 (n=32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24100","value":"19000"}]}],"title":"Day 8 (n=32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27300","value":"31600"}]}],"title":"Day 15 (n=28)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20600","value":"36400"}]}],"title":"Day 29 (n=33)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17300","value":"27500"}]}],"title":"Week 9 (n=32)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12400","value":"23300"}]}],"title":"Week 13 (n=25)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9700","value":"19900"}]}],"title":"Week 25 (n=23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8900","value":"21400"}]}],"title":"Week 49 (n=9)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg dose on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.","id":"OG000","title":"Denosumab"}],"paramType":"MEAN","populationDescription":"The pharmacokinetics analysis set included participants who received at least 1 dose of denosumab and for whom at least 1 serum denosumab trough concentration was available. 'n' indicates the number of participants with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Blood samples were collected on Days 1 (baseline), 8, 15 and Weeks 5 (Day 29), 9, 13, 25, and 49.","title":"Serum Denosumab Trough Concentrations","type":"SECONDARY","unitOfMeasure":"ng/mL"}